Ubs Group Ag Trevi Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 298,612 shares of TRVI stock, worth $3.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

298,612

Previous 354,225 15.7%

Holding current value

$3.38 Million

Previous $1.94 Million 37.79%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$5.62 - $9.62 $312,545 - $534,997	-55,613 Reduced 15.7%	298,612 $2.67 Million
Q2 2025 Aug 14, 2025	BUY	$5.28 - $7.06 $1.38 Million - $1.84 Million	261,192 Added 280.75%	354,225 $1.94 Million
Q1 2025 May 13, 2025	BUY	$3.66 - $6.81 $173,915 - $323,597	47,518 Added 104.4%	93,033 $585,000
Q4 2024 Feb 14, 2025	BUY	$2.53 - $4.5 $44,662 - $79,438	17,653 Added 63.36%	45,515 $193,000
Q3 2024 Nov 14, 2024	BUY	$2.58 - $3.51 $25,420 - $34,584	9,853 Added 54.71%	27,862 $93,000

Q2 2024 Aug 13, 2024	SELL	$2.44 - $3.36 $58,825 - $81,006	-24,109 Reduced 57.24%	18,009 $53,000
Q1 2024 May 13, 2024	BUY	$1.3 - $3.7 $13,963 - $39,741	10,741 Added 34.23%	42,118 $145,000
Q4 2023 Feb 09, 2024	BUY	$1.06 - $2.05 $9,330 - $18,044	8,802 Added 38.99%	31,377 $42,000
Q3 2023 Nov 09, 2023	SELL	$2.11 - $2.47 $3,122 - $3,655	-1,480 Reduced 6.15%	22,575 $49,000
Q2 2023 Aug 11, 2023	BUY	$1.8 - $3.44 $29,655 - $56,674	16,475 Added 217.35%	24,055 $57,000
Q1 2023 May 12, 2023	BUY	$1.69 - $2.97 $7,586 - $13,332	4,489 Added 145.23%	7,580 $14,000
Q4 2022 Feb 08, 2023	SELL	$1.61 - $2.42 $1,909 - $2,870	-1,186 Reduced 27.73%	3,091 $5,000
Q3 2022 Nov 10, 2022	SELL	$1.54 - $4.28 $760 - $2,114	-494 Reduced 10.35%	4,277 $7,000
Q2 2022 Aug 10, 2022	BUY	$1.8 - $3.39 $5,664 - $10,668	3,147 Added 193.78%	4,771 $13,000
Q1 2022 May 16, 2022	BUY	$0.46 - $2.48 $747 - $4,027	1,624 New	1,624 $4,000
Q4 2021 Feb 14, 2022	SELL	$0.68 - $1.5 $3,517 - $7,759	-5,173 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.29 - $2.18 $3,916 - $6,618	3,036 Added 142.07%	5,173 $7,000
Q2 2021 Aug 13, 2021	SELL	$2.0 - $2.76 $482 - $665	-241 Reduced 10.13%	2,137 $5,000
Q1 2021 May 12, 2021	BUY	$2.36 - $3.55 $5,612 - $8,441	2,378 New	2,378 $6,000
Q2 2020 Jul 31, 2020	SELL	$2.51 - $6.87 $1,357 - $3,716	-541 Closed	0 $0
Q1 2020 May 01, 2020	BUY	$1.71 - $5.87 $925 - $3,175	541 New	541 $2,000
Q4 2019 Feb 14, 2020	SELL	$2.78 - $4.7 $4,384 - $7,411	-1,577 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$4.2 - $7.79 $1,444 - $2,679	-344 Reduced 17.91%	1,577 $7,000
Q2 2019 Aug 14, 2019	BUY	$7.5 - $10.12 $14,407 - $19,440	1,921 New	1,921 $14,000

Others Institutions Holding TRVI

# of Institutions

174

Shares Held

119M

Call Options Held

629K

Put Options Held

1.22M

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $661M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account